VRTX logo

VRTX Revenue

VRTX Annual Revenue

$9.87 B
+$938.50 M+10.51%

31 December 2023

VRTX Revenue Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

VRTX Quarterly Revenue

$2.77 B
+$126.30 M+4.77%

30 September 2024

VRTX Quarterly Revenue Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

VRTX TTM Revenue

$10.63 B
+$288.40 M+2.79%

30 September 2024

VRTX TTM Revenue Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

VRTX Revenue Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10.5%+3.0%+4.3%
3 y3 years+59.0%+3.0%+4.3%
5 y5 years+223.8%+96.1%+155.3%

VRTX Revenue High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+30.3%at high+33.7%at high+40.3%
5 y5-yearat high+137.1%at high+96.1%at high+155.3%
alltimeall timeat high>+9999.0%at high+9138.4%at high>+9999.0%

Vertex Pharmaceuticals Incorporated Revenue History

DateAnnualQuarterlyTTM
Sept 2024
-
$2.77 B(+4.8%)
$10.63 B(+2.8%)
June 2024
-
$2.65 B(-1.7%)
$10.34 B(+1.5%)
Mar 2024
-
$2.69 B(+6.9%)
$10.19 B(+3.2%)
Dec 2023
$9.87 B(+10.5%)
$2.52 B(+1.4%)
$9.87 B(+2.2%)
Sept 2023
-
$2.48 B(-0.4%)
$9.65 B(+1.6%)
June 2023
-
$2.49 B(+5.0%)
$9.51 B(+3.2%)
Mar 2023
-
$2.37 B(+3.1%)
$9.21 B(+3.1%)
Dec 2022
$8.93 B(+17.9%)
$2.30 B(-1.4%)
$8.93 B(+2.6%)
Sept 2022
-
$2.33 B(+6.3%)
$8.70 B(+4.2%)
June 2022
-
$2.20 B(+4.7%)
$8.35 B(+5.1%)
Mar 2022
-
$2.10 B(+1.2%)
$7.95 B(+4.9%)
Dec 2021
$7.57 B(+22.1%)
$2.07 B(+4.5%)
$7.57 B(+6.2%)
Sept 2021
-
$1.98 B(+10.6%)
$7.13 B(+6.7%)
June 2021
-
$1.79 B(+4.0%)
$6.68 B(+4.2%)
Mar 2021
-
$1.72 B(+5.9%)
$6.41 B(+3.4%)
Dec 2020
$6.21 B(+49.1%)
$1.63 B(+5.8%)
$6.21 B(+3.6%)
Sept 2020
-
$1.54 B(+0.9%)
$5.99 B(+10.9%)
June 2020
-
$1.52 B(+0.6%)
$5.40 B(+12.1%)
Mar 2020
-
$1.52 B(+7.2%)
$4.82 B(+15.8%)
Dec 2019
$4.16 B(+36.6%)
$1.41 B(+48.8%)
$4.16 B(+15.0%)
Sept 2019
-
$949.83 M(+0.9%)
$3.62 B(+4.8%)
June 2019
-
$941.29 M(+9.7%)
$3.45 B(+5.8%)
Mar 2019
-
$858.43 M(-1.3%)
$3.27 B(+7.1%)
Dec 2018
$3.05 B(+22.5%)
$870.11 M(+10.9%)
$3.05 B(+7.7%)
Sept 2018
-
$784.53 M(+4.3%)
$2.83 B(+7.9%)
June 2018
-
$752.16 M(+17.4%)
$2.62 B(+8.6%)
Mar 2018
-
$640.80 M(-1.7%)
$2.41 B(-3.0%)
Dec 2017
$2.49 B(+46.2%)
$651.63 M(+12.7%)
$2.49 B(+8.4%)
Sept 2017
-
$578.16 M(+6.3%)
$2.30 B(+7.7%)
June 2017
-
$544.13 M(-23.9%)
$2.13 B(+5.6%)
Mar 2017
-
$714.72 M(+55.8%)
$2.02 B(+18.6%)
Dec 2016
$1.70 B(+64.9%)
$458.71 M(+10.9%)
$1.70 B(+2.5%)
Sept 2016
-
$413.78 M(-4.1%)
$1.66 B(+6.7%)
June 2016
-
$431.61 M(+8.4%)
$1.56 B(+20.6%)
Mar 2016
-
$398.08 M(-4.8%)
$1.29 B(+25.1%)
Dec 2015
$1.03 B(+77.9%)
$417.94 M(+34.9%)
$1.03 B(+36.0%)
Sept 2015
-
$309.82 M(+86.6%)
$758.96 M(+20.8%)
June 2015
-
$166.08 M(+19.9%)
$628.13 M(+4.6%)
Mar 2015
-
$138.51 M(-4.2%)
$600.47 M(+3.5%)
Dec 2014
$580.41 M(-52.1%)
$144.56 M(-19.2%)
$580.41 M(-26.3%)
Sept 2014
-
$178.99 M(+29.3%)
$787.02 M(-5.1%)
June 2014
-
$138.42 M(+16.9%)
$829.73 M(-17.2%)
Mar 2014
-
$118.45 M(-66.3%)
$1.00 B(-17.3%)
Dec 2013
$1.21 B(-20.6%)
$351.16 M(+58.4%)
$1.21 B(+1.4%)
Sept 2013
-
$221.70 M(-28.7%)
$1.19 B(-8.7%)
June 2013
-
$310.75 M(-5.4%)
$1.31 B(-7.6%)
Mar 2013
-
$328.37 M(-1.7%)
$1.42 B(-7.2%)
Dec 2012
$1.53 B(+8.3%)
$333.99 M(-0.6%)
$1.53 B(-13.1%)
Sept 2012
-
$336.01 M(-19.7%)
$1.76 B(-15.5%)
June 2012
-
$418.31 M(-4.7%)
$2.08 B(+17.1%)
Mar 2012
-
$438.74 M(-22.1%)
$1.78 B(+25.9%)
Dec 2011
$1.41 B(+883.9%)
$563.34 M(-14.5%)
$1.41 B(+54.5%)
Sept 2011
-
$659.20 M(+476.1%)
$912.81 M(+229.1%)
June 2011
-
$114.42 M(+55.3%)
$277.40 M(+42.5%)
Mar 2011
-
$73.66 M(+12.4%)
$194.60 M(+35.7%)
Dec 2010
$143.37 M(+40.7%)
$65.52 M(+175.4%)
$143.37 M(+28.3%)
Sept 2010
-
$23.80 M(-24.8%)
$111.73 M(-1.0%)
June 2010
-
$31.62 M(+41.0%)
$112.90 M(+12.5%)
Mar 2010
-
$22.43 M(-33.8%)
$100.34 M(-1.5%)
Dec 2009
$101.89 M(-41.9%)
$33.89 M(+35.8%)
$101.89 M(+1.1%)
Sept 2009
-
$24.96 M(+30.9%)
$100.81 M(-6.2%)
June 2009
-
$19.06 M(-20.5%)
$107.46 M(-31.9%)
Mar 2009
-
$23.98 M(-26.9%)
$157.81 M(-10.1%)
Dec 2008
$175.50 M(-11.8%)
$32.81 M(+3.8%)
$175.50 M(-9.4%)
Sept 2008
-
$31.61 M(-54.5%)
$193.69 M(-4.6%)
June 2008
-
$69.41 M(+66.5%)
$203.09 M(+18.2%)
Mar 2008
-
$41.67 M(-18.3%)
$171.88 M(-13.6%)
Dec 2007
$199.01 M
$50.99 M(+24.3%)
$199.01 M(-17.9%)
Sept 2007
-
$41.01 M(+7.4%)
$242.27 M(-4.8%)
DateAnnualQuarterlyTTM
June 2007
-
$38.20 M(-44.5%)
$254.55 M(+3.4%)
Mar 2007
-
$68.81 M(-27.0%)
$246.08 M(+13.7%)
Dec 2006
$216.36 M(+34.5%)
$94.25 M(+76.9%)
$216.36 M(+16.4%)
Sept 2006
-
$53.29 M(+79.3%)
$185.86 M(+10.1%)
June 2006
-
$29.73 M(-23.9%)
$168.78 M(-1.5%)
Mar 2006
-
$39.09 M(-38.7%)
$171.37 M(+6.5%)
Dec 2005
$160.89 M(+56.6%)
$63.76 M(+76.1%)
$160.89 M(+17.5%)
Sept 2005
-
$36.21 M(+12.0%)
$136.97 M(+7.4%)
June 2005
-
$32.32 M(+13.0%)
$127.59 M(+12.1%)
Mar 2005
-
$28.61 M(-28.2%)
$113.81 M(+10.8%)
Dec 2004
$102.72 M(+48.6%)
$39.84 M(+48.5%)
$102.72 M(+21.9%)
Sept 2004
-
$26.83 M(+44.7%)
$84.26 M(+15.0%)
June 2004
-
$18.54 M(+5.9%)
$73.25 M(+1.3%)
Mar 2004
-
$17.51 M(-18.1%)
$72.29 M(-6.6%)
Dec 2003
$69.14 M(-27.0%)
$21.38 M(+35.1%)
$77.39 M(+131.2%)
Sept 2003
-
$15.82 M(-10.0%)
$33.48 M(-35.5%)
June 2003
-
$17.58 M(-22.3%)
$51.93 M(-32.3%)
Mar 2003
-
$22.61 M(-200.3%)
$76.68 M(-19.1%)
Dec 2002
$94.77 M(+11.1%)
-$22.53 M(-165.7%)
$94.77 M(+9.4%)
Sept 2002
-
$34.28 M(-19.0%)
$86.63 M(-6.6%)
June 2002
-
$42.33 M(+4.0%)
$92.72 M(+29.1%)
Mar 2002
-
$40.70 M(-232.7%)
$71.84 M(+43.1%)
Dec 2001
$85.30 M(-44.4%)
-$30.67 M(-176.0%)
$50.20 M(-71.4%)
Sept 2001
-
$40.37 M(+88.3%)
$175.73 M(+17.8%)
June 2001
-
$21.44 M(+12.5%)
$149.22 M(-9.5%)
Mar 2001
-
$19.06 M(-79.9%)
$164.82 M(+7.1%)
Dec 2000
$153.28 M(+202.9%)
$94.86 M(+584.1%)
$153.89 M(+79.1%)
Sept 2000
-
$13.87 M(-62.6%)
$85.93 M(+8.4%)
June 2000
-
$37.03 M(+355.4%)
$79.26 M(+44.8%)
Mar 2000
-
$8.13 M(-69.8%)
$54.74 M(+8.2%)
Dec 1999
$50.60 M(+73.9%)
$26.90 M(+273.6%)
$50.61 M(+151.6%)
Sept 1999
-
$7.20 M(-42.5%)
$20.12 M(-35.8%)
June 1999
-
$12.52 M(+212.9%)
$31.32 M(+20.4%)
Mar 1999
-
$4.00 M(-211.1%)
$26.00 M(+3.2%)
Dec 1998
$29.10 M(-33.6%)
-$3.60 M(-119.6%)
$25.20 M(-37.0%)
Sept 1998
-
$18.40 M(+155.6%)
$40.00 M(+14.0%)
June 1998
-
$7.20 M(+125.0%)
$35.10 M(-12.5%)
Mar 1998
-
$3.20 M(-71.4%)
$40.10 M(-8.4%)
Dec 1997
$43.80 M(+135.5%)
$11.20 M(-17.0%)
$43.80 M(+2.6%)
Sept 1997
-
$13.50 M(+10.7%)
$42.70 M(+33.0%)
June 1997
-
$12.20 M(+76.8%)
$32.10 M(+39.6%)
Mar 1997
-
$6.90 M(-31.7%)
$23.00 M(+23.7%)
Dec 1996
$18.60 M(-15.8%)
$10.10 M(+248.3%)
$18.60 M(+11.4%)
Sept 1996
-
$2.90 M(-6.5%)
$16.70 M(+3.7%)
June 1996
-
$3.10 M(+24.0%)
$16.10 M(-17.4%)
Mar 1996
-
$2.50 M(-69.5%)
$19.50 M(-11.8%)
Dec 1995
$22.10 M(+12.8%)
$8.20 M(+256.5%)
$22.10 M(+33.1%)
Sept 1995
-
$2.30 M(-64.6%)
$16.60 M(-20.2%)
June 1995
-
$6.50 M(+27.5%)
$20.80 M(+8.9%)
Mar 1995
-
$5.10 M(+88.9%)
$19.10 M(-2.6%)
Dec 1994
$19.60 M(-29.7%)
$2.70 M(-58.5%)
$19.60 M(-43.8%)
Sept 1994
-
$6.50 M(+35.4%)
$34.90 M(+6.4%)
June 1994
-
$4.80 M(-14.3%)
$32.80 M(+0.6%)
Mar 1994
-
$5.60 M(-68.9%)
$32.60 M(+16.8%)
Dec 1993
$27.90 M(+634.2%)
$18.00 M(+309.1%)
$27.90 M(+156.0%)
Sept 1993
-
$4.40 M(-4.3%)
$10.90 M(+45.3%)
June 1993
-
$4.60 M(+411.1%)
$7.50 M(+92.3%)
Mar 1993
-
$900.00 K(-10.0%)
$3.90 M(0.0%)
Dec 1992
$3.80 M(+18.8%)
$1.00 M(0.0%)
$3.90 M(+5.4%)
Sept 1992
-
$1.00 M(0.0%)
$3.70 M(+5.7%)
June 1992
-
$1.00 M(+11.1%)
$3.50 M(+6.1%)
Mar 1992
-
$900.00 K(+12.5%)
$3.30 M(+3.1%)
Dec 1991
$3.20 M(+39.1%)
$800.00 K(0.0%)
$3.20 M(+6.7%)
Sept 1991
-
$800.00 K(0.0%)
$3.00 M(+7.1%)
June 1991
-
$800.00 K(0.0%)
$2.80 M(+7.7%)
Mar 1991
-
$800.00 K(+33.3%)
$2.60 M(+13.0%)
Dec 1990
$2.30 M
$600.00 K(0.0%)
$2.30 M(+35.3%)
Sept 1990
-
$600.00 K(0.0%)
$1.70 M(+54.5%)
June 1990
-
$600.00 K(+20.0%)
$1.10 M(+120.0%)
Mar 1990
-
$500.00 K
$500.00 K

FAQ

  • What is Vertex Pharmaceuticals Incorporated annual revenue?
  • What is the all time high annual revenue for Vertex Pharmaceuticals Incorporated?
  • What is Vertex Pharmaceuticals Incorporated annual revenue year-on-year change?
  • What is Vertex Pharmaceuticals Incorporated quarterly revenue?
  • What is the all time high quarterly revenue for Vertex Pharmaceuticals Incorporated?
  • What is Vertex Pharmaceuticals Incorporated quarterly revenue year-on-year change?
  • What is Vertex Pharmaceuticals Incorporated TTM revenue?
  • What is the all time high TTM revenue for Vertex Pharmaceuticals Incorporated?
  • What is Vertex Pharmaceuticals Incorporated TTM revenue year-on-year change?

What is Vertex Pharmaceuticals Incorporated annual revenue?

The current annual revenue of VRTX is $9.87 B

What is the all time high annual revenue for Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated all-time high annual revenue is $9.87 B

What is Vertex Pharmaceuticals Incorporated annual revenue year-on-year change?

Over the past year, VRTX annual revenue has changed by +$938.50 M (+10.51%)

What is Vertex Pharmaceuticals Incorporated quarterly revenue?

The current quarterly revenue of VRTX is $2.77 B

What is the all time high quarterly revenue for Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated all-time high quarterly revenue is $2.77 B

What is Vertex Pharmaceuticals Incorporated quarterly revenue year-on-year change?

Over the past year, VRTX quarterly revenue has changed by +$81.30 M (+3.02%)

What is Vertex Pharmaceuticals Incorporated TTM revenue?

The current TTM revenue of VRTX is $10.63 B

What is the all time high TTM revenue for Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated all-time high TTM revenue is $10.63 B

What is Vertex Pharmaceuticals Incorporated TTM revenue year-on-year change?

Over the past year, VRTX TTM revenue has changed by +$440.80 M (+4.33%)